Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

191. »Lab282« Accelerates with Second Round Funding

»Lab282« Accelerates with Second Round Funding20/06/2017The drug discovery partnership between Oxford University, Evotec and Oxford Sciences Innovation Awards five new life sciences projectsEvotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University.LAB282 is providing critical early stage g


192. Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relat

Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relations05/06/2017OXFORD, United Kingdom and MARLBOROUGH, Mass., June 5, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Karen Koski as Head of Strategy and Investor Relations. The newly created position will repor


193. Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at t

Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress23/06/2017Summit Therapeutics plc('Summit', or 'the Company')SUMMIT PRESENTS DATA FROM PHASE 1 CLINICAL PROGRAMME OF EZUTROMID AT THE EUROPEAN PAEDIATRIC NEUROLOGY SOCIETY CONGRESSSummit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, today announces the presentation


194. Exscientia enters strategic drug discovery collaboration with GSK

Exscientia enters strategic drug discovery collaboration with GSK05/07/2017Pre-clinical collaboration focused on up to 10 targets nominated by GSKExscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce it has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During this collaboration, Exscientia will apply its AI enabled platform and combine this with the expertise of GSK, in order to discove


195. Immunocore and MEPC announce significant laboratory expansion at Milto

Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK10/07/2017Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, and MEPC Limited (MEPC), a leading property developer and asset manager, announced today that Immunocore will expand its operations at Milton Park in Oxfordshire initially by a further 53,000 square feet (sq ft). The new purpose-built research lab



Page 39 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019